About: Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale
Creator	Frontera, Jennifer Helbok, Raimund Kochanek, Patrick Menon, David Suarez, Jose Mainali, Shraddha Chou, -Y Fink, Ericka Mcnett, Molly Robertson, Courtney Schober, Michelle Ziai, Wendy
Source	Medline; PMC
abstract	BACKGROUND: As the COVID-19 pandemic developed, reports of neurological dysfunctions spanning the central and peripheral nervous systems have emerged. The spectrum of acute neurological dysfunctions may implicate direct viral invasion, para-infectious complications, neurological manifestations of systemic diseases, or co-incident neurological dysfunction in the context of high SARS-CoV-2 prevalence. A rapid and pragmatic approach to understanding the prevalence, phenotypes, pathophysiology and prognostic implications of COVID-19 neurological syndromes is urgently needed. METHODS: The Global Consortium to Study Neurological dysfunction in COVID-19 (GCS-NeuroCOVID), endorsed by the Neurocritical Care Society (NCS), was rapidly established to address this need in a tiered approach. Tier-1 consists of focused, pragmatic, low-cost, observational common data element (CDE) collection, which can be launched immediately at many sites in the first phase of this pandemic and is designed for expedited ethical board review with waiver-of-consent. Tier 2 consists of prospective functional and cognitive outcomes assessments with more detailed clinical, laboratory and radiographic data collection that would require informed consent. Tier 3 overlays Tiers 1 and 2 with experimental molecular, electrophysiology, pathology and imaging studies with longitudinal outcomes assessment and would require centers with specific resources. A multicenter pediatrics core has developed and launched a parallel study focusing on patients ages <18 years. Study sites are eligible for participation if they provide clinical care to COVID-19 patients and are able to conduct patient-oriented research under approval of an internal or global ethics committee. Hospitalized pediatric and adult patients with SARS-CoV-2 and with acute neurological signs or symptoms are eligible to participate. The primary study outcome is the overall prevalence of neurological complications among hospitalized COVID-19 patients, which will be calculated by pooled estimates of each neurological finding divided by the average census of COVID-19 positive patients over the study period. Secondary outcomes include: in-hospital, 30 and 90-day morality, discharge modified Rankin score, ventilator-free survival, ventilator days, discharge disposition, and hospital length of stay. RESULTS: In a one-month period (3/27/20–4/27/20) the GCS-NeuroCOVID consortium was able to recruit 71 adult study sites, representing 17 countries and 5 continents and 34 pediatrics study sites. CONCLUSIONS: This is one of the first large-scale global research collaboratives urgently assembled to evaluate acute neurological events in the context of a pandemic. The innovative and pragmatic tiered study approach has allowed for rapid recruitment and activation of numerous sites across the world—an approach essential to capture real-time critical neurological data to inform treatment strategies in this pandemic crisis.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1007/s12028-020-00995-3
bibo:pmid	32445105
has license	no-cc
sha1sum (hex)	2e43703c701890f62073b11b8881bd32549d9654
schema:url	https://doi.org/10.1007/s12028-020-00995-3
resource representing a document's title	Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale
has PubMed Central identifier	PMC7243953
has PubMed identifier	32445105
schema:publication	Neurocrit Care
resource representing a document's body	covid:2e43703c701890f62073b11b8881bd32549d9654#body_text
is schema:about of	named entity 'neurological syndromes' named entity 'Consortium' named entity 'INFECTIOUS COMPLICATIONS' named entity 'APPROACH' named entity 'BACKGROUND' covid:arg/2e43703c701890f62073b11b8881bd32549d9654 named entity 'The spectrum' named entity 'complications' named entity 'COVID-19' named entity 'viral' named entity 'COVID' named entity 'neurological' named entity 'neurological dysfunction' named entity 'neurological' named entity 'peripheral nervous systems' named entity 'Neurological Dysfunction' named entity 'pathophysiology' named entity 'CNS' named entity 'neurological syndromes' named entity 'COVID' named entity 'pediatric' named entity 'neuromuscular blockade' named entity 'SARS-CoV-2' named entity 'Guillain-Barre syndrome' named entity 'neurological symptoms' named entity 'COVID' named entity 'H1N1' named entity 'olfactory bulb' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'brain tissue' named entity 'COVID-19 pandemic' named entity 'neuropathy' named entity 'Bivariate analysis' named entity 'COVID' named entity 'neurological dysfunction' named entity 'long-term' named entity 'neurological symptoms' named entity 'neurological dysfunction' named entity 'neurological complications' named entity 'infection' named entity 'ordinal level' named entity 'SARS-CoV-2' named entity 'pathophysiologic' named entity 'quadriparesis' named entity 'social distancing' named entity 'microcephaly' named entity 'protein' named entity 'pediatric' named entity 'status epilepticus' named entity 'radiographic' named entity 'telecommunication' named entity 'organ failure' named entity 'meningitis' named entity 'etiology' named entity 'COVID' named entity 'parallel processing' named entity 'COVID' named entity 'CSF' named entity 'peer-reviewed' named entity 'infection' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'neurological dysfunction' named entity 'SARS-CoV-2' named entity 'comorbidities' named entity 'radiographic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software